A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 For Prevention of Recurrent Clostridioides Difficile Infection

Date Added
September 12th, 2024
PRO Number
Pro00135241
Researcher
Scott Curry

List of Studies


Keywords
Infectious Diseases
Summary

The primary objective of this study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate in participants who receive a 14-day course of VE303 or matching placebo.
Other objective is to measure health-related quality of life and daily CDI symptoms in participants treated with VE303 versus placebo.

Institution
MUSC
Recruitment Contact
Alicia Hartley
843-792-4100
hartleal@musc.edu



-- OR --